New Incubate Op-Ed in Triangle Business Journal: With One "EPIC" Fix, Congress Can Save Lives

In their new opinion piece for the Triangle Business Journal, Incubate executive director John Stanford and Patrick Jordan, managing partner of NovaQuest Capital Management and chairman of Mycovia Pharmaceuticals, detail how the pill penalty will impact North Carolina's booming life sciences industry.

They urge Congress to pass the Ensuring Pathways to Innovative Cures (EPIC) Act, bipartisan legislation introduced in the House and Senate that would undo the pill penalty, restoring incentives to invest in and develop small-molecule medicines.

Triangle Business Journal:

Thankfully, North Carolina's leaders in Washington are stepping up: senators Thom Tillis and Ted Budd and reps. Greg Murphy, Don Davis and Richard Hudson introduced the EPIC Act, a fix that would level the playing field by giving small-molecule medicines the same 13-year exemption from price controls as biologics. This would restore investor confidence and get critical research back on track.

When people think of life sciences, they often picture Massachusetts or California. But when it comes to driving real change in Washington, it's North Carolina leading the charge. Our congressional delegation deserves credit for standing up for our economy, jobs and research that saves lives.